X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Torrent Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA TORRENT PHARMA AJANTA PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 28.5 29.4 96.8% View Chart
P/BV x 11.7 5.6 209.9% View Chart
Dividend Yield % 0.5 1.0 52.5%  

Financials

 AJANTA PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
TORRENT PHARMA
Mar-17
AJANTA PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7201,768 97.3%   
Low Rs1,1031,186 93.0%   
Sales per share (Unadj.) Rs194.6346.1 56.2%  
Earnings per share (Unadj.) Rs45.255.2 82.0%  
Cash flow per share (Unadj.) Rs50.373.3 68.6%  
Dividends per share (Unadj.) Rs8.0014.00 57.1%  
Dividend yield (eoy) %0.60.9 59.8%  
Book value per share (Unadj.) Rs132.0257.1 51.4%  
Shares outstanding (eoy) m88.77169.22 52.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.34.3 170.0%   
Avg P/E ratio x31.226.8 116.6%  
P/CF ratio (eoy) x28.120.1 139.3%  
Price / Book Value ratio x10.75.7 186.1%  
Dividend payout %17.725.4 69.7%   
Avg Mkt Cap Rs m125,299249,887 50.1%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m2,5709,934 25.9%   
Avg. sales/employee Rs ThNM4,971.5-  
Avg. wages/employee Rs ThNM843.2-  
Avg. net profit/employee Rs ThNM792.4-  
INCOME DATA
Net Sales Rs m17,27558,569 29.5%  
Other income Rs m1662,233 7.4%   
Total revenues Rs m17,44260,802 28.7%   
Gross profit Rs m5,80713,773 42.2%  
Depreciation Rs m4513,069 14.7%   
Interest Rs m492,056 2.4%   
Profit before tax Rs m5,47410,881 50.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4601,545 94.5%   
Profit after tax Rs m4,0149,336 43.0%  
Gross profit margin %33.623.5 143.0%  
Effective tax rate %26.714.2 187.8%   
Net profit margin %23.215.9 145.8%  
BALANCE SHEET DATA
Current assets Rs m7,63953,841 14.2%   
Current liabilities Rs m2,71531,612 8.6%   
Net working cap to sales %28.538.0 75.1%  
Current ratio x2.81.7 165.2%  
Inventory Days Days4397 44.5%  
Debtors Days Days7984 93.9%  
Net fixed assets Rs m6,91442,079 16.4%   
Share capital Rs m177846 20.9%   
"Free" reserves Rs m11,44242,655 26.8%   
Net worth Rs m11,72143,501 26.9%   
Long term debt Rs m14922,408 0.7%   
Total assets Rs m14,814101,250 14.6%  
Interest coverage x112.96.3 1,794.7%   
Debt to equity ratio x00.5 2.5%  
Sales to assets ratio x1.20.6 201.6%   
Return on assets %27.411.3 243.8%  
Return on equity %34.221.5 159.6%  
Return on capital %46.519.6 237.1%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,42220,066 51.9%   
Fx outflow Rs m1,6785,304 31.6%   
Net fx Rs m8,74414,762 59.2%   
CASH FLOW
From Operations Rs m3,26410,127 32.2%  
From Investments Rs m-2,093-7,869 26.6%  
From Financial Activity Rs m-1,186-1,918 61.8%  
Net Cashflow Rs m-15212 -7.0%  

Share Holding

Indian Promoters % 73.8 71.5 103.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 7.0 22.1%  
FIIs % 7.6 12.6 60.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 8.8 193.2%  
Shareholders   20,968 26,511 79.1%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   GLENMARK PHARMA  J.B.CHEMICALS  MERCK LTD  BIOCON LTD  FULFORD INDIA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Rally, IMF's GDP Prediction, and Top Stocks in Action(Pre-Open)

On Tuesday, share markets in India opened in green and ended on a positive note. The BSE Sensex closed higher by 342 points to close above 36,000 levels for the first time ever.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 23, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - GSK PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS